KẾT QUẢ ĐIỀU TRỊ BƯỚC HAI UNG THƯ VÚ TÁI PHÁT DI CĂN CÓ THỤ THỂ NỘI TIẾT DƯƠNG TÍNH HER ÂM TÍNH BẰNG FULVESTRANT

Abstract

Objectives: To evaluate the results of second-line treatment of patients with recurrent, metastatic hormone receptor-positive her-negative breast cancer with fulvestrant. Subjects and methods: Using a retrospective and prospective design with a convenient sample size, 36 patients with hormone receptor-positive, metastatic, recurrent breast cancer were treated with second-step endocrine therapy by fulvestrant from 1/2017 to 8/2022 at Hanoi Oncology Hospital. Result: Patients who achieved partial response accounted for 33.3%, patients with disease remained accounted for 47.2%, and the proportion of patient with progressive disease was 19.5%. There was no patient achieved a complete response. Progression-free survival was 7.1 ± 0.8 months. Conclusion: Fulvestrant is an effective endocrine drug, early treatment should be considered in patients with breast cancer with metastatic recurrence, positive hormone receptors, low tumor burden. First-line treatment will be more effective than subsequent treatment steps.